Healthcare / BiotechnologyCboe UK
$0.73
-0.01 (-1.35%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-1.3M · quality 50.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4M
P/E
178.0x
↑EV/EBITDA
161.3x
↑ROE
14.4%
↑Gross Margin
69.6%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-9.6%
FCF / Net income
-1.03x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $13.9M · net income $1.3M · FCF $-1.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $13.9M | $13.9M | $3.1M | — | — |
| Net Income | $1.3M | $1.3M | $-6.5M | $-5.8M | $-5.0M |
| EBITDA | $1.4M | $1.4M | $-6.8M | $-6.8M | $-5.8M |
| EPS | 0.00 | 0.00 | 0.02 | -0.02 | -0.02 |
| Gross Margin | 69.6% | 69.6% | 57.2% | — | — |
| Operating Margin | 8.9% | 8.9% | -224.6% | — | — |
| Net Margin | 9.3% | 9.3% | -210.0% | — | — |
| Balance Sheet | |||||
| Current Ratio | 2.23 | 2.23 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.3M | $-1.3M | $-935596.00 | $-6.5M | $-4.3M |
| Returns | |||||
| ROE | 14.4% | 14.4% | -118.9% | -123.9% | -51.0% |
| Valuation | |||||
| P/E | 178.05 | 178.05 | — | — | — |
| EV/EBITDA | 161.28 | 161.28 | — | — | — |
| P/B | 25.31 | 25.31 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 349.1% | 349.1% | — | — | — |
| EPS Growth | -81.4% | -81.4% | 208.9% | -10.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
150.9%
EPS terminal req.
$0.06
Spread vs growth
-232.4%
5Y implied EPS CAGR
80.4%
EPS terminal req.
$0.08
Spread vs growth
-161.9%
10Y implied EPS CAGR
40.9%
EPS terminal req.
$0.13
Spread vs growth
-122.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-95.7%
Start / end P/E
767.4x → 178.0x
EPS bridge
0.02 → 0.00
Residual
+62.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.